Glenmede Trust’s Utah Medical Products UTMD Stock Holding History

Glenmede Trust’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19	Closed	-$1K	–	2224
2020 Q3	$1K	Buy	+19	New	+$1.58K	﹤0.01%	2398

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glenmede Trust's UTMD Position: Q4 2020 in Review

Glenmede Trust sold out of Utah Medical Products (UTMD) in Q4 2020, closing a stake of 19 shares — an estimated $1K sold.

Glenmede Trust first reported a position in UTMD in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 77 funds tracked by Wall St. Rank hold UTMD as of Q4 2020.

Glenmede Trust reported no remaining Utah Medical Products position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 19 Utah Medical Products shares in Q4 2020, an estimated $1K.
Glenmede Trust first reported a position in Utah Medical Products in Q3 2020 and held it in 1 quarter.
Glenmede Trust's Utah Medical Products position peaked at $1K in Q3 2020.
77 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.